Literature DB >> 27752972

In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead.

Lihui Weng1, Hsiang-Jer Tseng1, Parinaz Rostamzadeh1, Jafar Golzarian2.   

Abstract

Drug loadable bioresorbable microspheres (BRMS) are specially designed for the treatment of hypervascular tumors through arterial embolization. These microspheres consist of carboxymethyl chitosan crosslinked with carboxymethyl cellulose, and are available at different size ranges varying from 50 to 900 µm in diameter. Similar to commercially available non-resorbable drug eluting microspheres, LC Bead® microspheres (LCB), BRMS were capable of loading more than 99 % of doxorubicin, an anticancer drug, from the solution within 2 h with highly similar kinetics (difference factor f 1 = 0.36; similarity factor f 2 = 97.99). Doxorubicin loaded BRMS exhibited the highest elution rate in the 30 % ethanol aqueous solution saturated with potassium chloride, and the elution time depended on the ratio between the amount of loaded BRMS and the volume of elution media. After injection through microcatheters, BRMS have a higher recovery rate of the microsphere weight than LCB (90.96 vs. 79.63 %, P = 0.026). Although loaded BRMS eluted more drug into the injection medium than loaded LCB (8.63 vs. 3.80 %, P = 0.0015), there was no significant difference in the drug delivery rate between BRMS and LCB (83.88 vs. 86.65 %, P = 0.504). This study compares the loading capability as well as the drug delivery rate of BRMS and a commercial product under a condition simulating a transcatheter arterial chemoembolization procedure and demonstrates the potential of drug loaded BRMS for the treatment of hypervascular tumors such as hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27752972     DOI: 10.1007/s10856-016-5786-2

Source DB:  PubMed          Journal:  J Mater Sci Mater Med        ISSN: 0957-4530            Impact factor:   3.896


  31 in total

1.  In vitro and in vivo evaluation of chitosan microspheres with different deacetylation degree as potential embolic agent.

Authors:  Xuan Zhou; Ming Kong; Xiao Jie Cheng; Chao Feng; Jing Li; Jing Jing Li; Xi Guang Chen
Journal:  Carbohydr Polym       Date:  2014-07-11       Impact factor: 9.381

2.  Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).

Authors:  Renumathy Dhanasekaran; David A Kooby; Charles A Staley; John S Kauh; Vinit Khanna; Hyun S Kim
Journal:  J Surg Oncol       Date:  2010-05-01       Impact factor: 3.454

3.  Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan.

Authors:  Olivier Jordan; Alban Denys; Thierry De Baere; Nathalie Boulens; Eric Doelker
Journal:  J Vasc Interv Radiol       Date:  2010-07       Impact factor: 3.464

4.  Interindividual variability in expression and activity of human beta-glucuronidase in liver and kidney: consequences for drug metabolism.

Authors:  B Sperker; T E Mürdter; M Schick; K Eckhardt; K Bosslet; H K Kroemer
Journal:  J Pharmacol Exp Ther       Date:  1997-05       Impact factor: 4.030

5.  New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel DC Bead™ for use in transarterial chemoembolization (TACE).

Authors:  Marco Biondi; Sabato Fusco; Andrew L Lewis; Paolo A Netti
Journal:  J Biomater Sci Polym Ed       Date:  2011-01-21       Impact factor: 3.517

6.  Doxorubicin eluting beads-2: methods for evaluating drug elution and in-vitro:in-vivo correlation.

Authors:  M Victoria Gonzalez; Yiqing Tang; Gary J Phillips; Andrew W Lloyd; Brenda Hall; Peter W Stratford; Andrew L Lewis
Journal:  J Mater Sci Mater Med       Date:  2007-07-25       Impact factor: 3.896

7.  Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC bead.

Authors:  Katerina Malagari; Efthimia Alexopoulou; Katerina Chatzimichail; Brenda Hall; John Koskinas; Samantha Ryan; Eva Gallardo; Alexis Kelekis; Athanassios Gouliamos; Dimitrios Kelekis
Journal:  Abdom Imaging       Date:  2008 Sep-Oct

8.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

9.  Immediate radical therapy or conservative treatments when meeting the Milan criteria for advanced HCC patients after successful TACE.

Authors:  L Jiang; J Y Lei; W T Wang; L N Yan; B Li; T F Wen; M Q Xu; J Y Yang; Y G Wei
Journal:  J Gastrointest Surg       Date:  2014-03-25       Impact factor: 3.452

10.  Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Authors:  Johannes Lammer; Katarina Malagari; Thomas Vogl; Frank Pilleul; Alban Denys; Anthony Watkinson; Michael Pitton; Geraldine Sergent; Thomas Pfammatter; Sylvain Terraz; Yves Benhamou; Yves Avajon; Thomas Gruenberger; Maria Pomoni; Herbert Langenberger; Marcus Schuchmann; Jerome Dumortier; Christian Mueller; Patrick Chevallier; Riccardo Lencioni
Journal:  Cardiovasc Intervent Radiol       Date:  2009-11-12       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.